Prepare More Data Earlier For Advisory Panels In Era Of Low Risk-Tolerance
This article was originally published in The Tan Sheet
Executive Summary
A stricter risk-tolerance environment at FDA means sponsors need to engage more in the advisory committee process and prepare to address real and perceived or hypothetical "data gaps.